{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T11:34:52Z","timestamp":1789644892819,"version":"4.0.0"},"reference-count":101,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T00:00:00Z","timestamp":1772841600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T00:00:00Z","timestamp":1773187200000},"content-version":"vor","delay-in-days":4,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Med"],"DOI":"10.1007\/s10238-026-02076-9","type":"journal-article","created":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T05:15:27Z","timestamp":1772860527000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["CAR-T therapy for autoimmune rheumatic diseases: navigating clinical frontiers between breakthroughs and uncertainties"],"prefix":"10.1007","volume":"26","author":[{"given":"Juntao","family":"Cheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuoli","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,7]]},"reference":[{"key":"2076_CR1","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1038\/s41584-021-00652-9","volume":"17","author":"Z Szekanecz","year":"2021","unstructured":"Szekanecz Z, et al. Autoinflammation and autoimmunity across rheumatic and musculoskeletal diseases. Nat Rev Rheumatol. 2021;17:585\u201395. https:\/\/doi.org\/10.1038\/s41584-021-00652-9.","journal-title":"Nat Rev Rheumatol"},{"key":"2076_CR2","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1038\/nrrheum.2010.86","volume":"6","author":"Y Shapira","year":"2010","unstructured":"Shapira Y, Agmon-Levin N, Shoenfeld Y. Geoepidemiology of autoimmune rheumatic diseases. Nat Rev Rheumatol. 2010;6:468\u201376. https:\/\/doi.org\/10.1038\/nrrheum.2010.86.","journal-title":"Nat Rev Rheumatol"},{"key":"2076_CR3","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1681\/asn.2013010026","volume":"24","author":"M Lech","year":"2013","unstructured":"Lech M, Anders HJ. The pathogenesis of lupus nephritis. J Am Soc Nephrol. 2013;24:1357\u201366. https:\/\/doi.org\/10.1681\/asn.2013010026.","journal-title":"J Am Soc Nephrol"},{"key":"2076_CR4","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/s0140-6736(22)01692-0","volume":"401","author":"ER Volkmann","year":"2023","unstructured":"Volkmann ER, Andr\u00e9asson K, Smith V. Systemic sclerosis. Lancet. 2023;401:304\u201318. https:\/\/doi.org\/10.1016\/s0140-6736(22)01692-0.","journal-title":"Lancet"},{"key":"2076_CR5","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1016\/j.jaad.2021.10.065","volume":"87","author":"R Jerjen","year":"2022","unstructured":"Jerjen R, Nikpour M, Krieg T, Denton CP, Saracino AM. Systemic sclerosis in adults. Part I: clinical features and pathogenesis. J Am Acad Dermatol. 2022;87:937\u201354. https:\/\/doi.org\/10.1016\/j.jaad.2021.10.065.","journal-title":"J Am Acad Dermatol"},{"key":"2076_CR6","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-021-00321-x","volume":"7","author":"IE Lundberg","year":"2021","unstructured":"Lundberg IE, et al. Idiopathic inflammatory myopathies. Nat Rev Dis Primers. 2021;7:86. https:\/\/doi.org\/10.1038\/s41572-021-00321-x.","journal-title":"Nat Rev Dis Primers"},{"key":"2076_CR7","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1136\/annrheumdis-2017-211468","volume":"76","author":"IE Lundberg","year":"2017","unstructured":"Lundberg IE, et al. 2017 European league against rheumatism\/American college of rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Ann Rheum Dis. 2017;76:1955\u201364. https:\/\/doi.org\/10.1136\/annrheumdis-2017-211468.","journal-title":"Ann Rheum Dis"},{"key":"2076_CR8","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1136\/annrheumdis-2016-209909","volume":"76","author":"O Kowal-Bielecka","year":"2017","unstructured":"Kowal-Bielecka O, et al. Update of EULAR recommendations for the treatment of systemic sclerosis. Ann Rheum Dis. 2017;76:1327\u201339. https:\/\/doi.org\/10.1136\/annrheumdis-2016-209909.","journal-title":"Ann Rheum Dis"},{"key":"2076_CR9","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1136\/ard-2023-224762","volume":"83","author":"A Fanouriakis","year":"2024","unstructured":"Fanouriakis A, et al. EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. Ann Rheum Dis. 2024;83:15\u201329. https:\/\/doi.org\/10.1136\/ard-2023-224762.","journal-title":"Ann Rheum Dis"},{"key":"2076_CR10","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1136\/annrheumdis-2021-220920","volume":"81","author":"RA Furie","year":"2022","unstructured":"Furie RA, et al. B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial. Ann Rheum Dis. 2022;81:100\u20137. https:\/\/doi.org\/10.1136\/annrheumdis-2021-220920.","journal-title":"Ann Rheum Dis"},{"key":"2076_CR11","doi-asserted-by":"publisher","first-page":"3044","DOI":"10.1002\/art.22810","volume":"56","author":"JH Anolik","year":"2007","unstructured":"Anolik JH, et al. Delayed memory B cell recovery in peripheral blood and lymphoid tissue in systemic lupus erythematosus after B cell depletion therapy. Arthritis Rheum. 2007;56:3044\u201356. https:\/\/doi.org\/10.1002\/art.22810.","journal-title":"Arthritis Rheum"},{"key":"2076_CR12","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1111\/ajt.12220","volume":"13","author":"EG Kamburova","year":"2013","unstructured":"Kamburova EG, et al. A single dose of rituximab does not deplete B cells in secondary lymphoid organs but alters phenotype and function. Am J Transplant. 2013;13:1503\u201311. https:\/\/doi.org\/10.1111\/ajt.12220.","journal-title":"Am J Transplant"},{"key":"2076_CR13","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1038\/s41573-020-00092-2","volume":"20","author":"DSW Lee","year":"2021","unstructured":"Lee DSW, Rojas OL, Gommerman JL. B cell depletion therapies in autoimmune disease: advances and mechanistic insights. Nat Rev Drug Discov. 2021;20:179\u201399. https:\/\/doi.org\/10.1038\/s41573-020-00092-2.","journal-title":"Nat Rev Drug Discov"},{"key":"2076_CR14","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1136\/annrheumdis-2019-216151","volume":"79","author":"KL Winthrop","year":"2020","unstructured":"Winthrop KL, et al. Unmet need in rheumatology: reports from the targeted therapies meeting 2019. Ann Rheum Dis. 2020;79:88\u201393. https:\/\/doi.org\/10.1136\/annrheumdis-2019-216151.","journal-title":"Ann Rheum Dis"},{"key":"2076_CR15","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01423","volume":"11","author":"S Kl\u00f6\u00df","year":"2020","unstructured":"Kl\u00f6\u00df S, et al. From cancer to immune-mediated diseases and tolerance induction: lessons learned from immune oncology and classical anti-cancer treatment. Front Immunol. 2020;11:1423. https:\/\/doi.org\/10.3389\/fimmu.2020.01423.","journal-title":"Front Immunol"},{"key":"2076_CR16","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14041078","author":"A Titov","year":"2022","unstructured":"Titov A, et al. Knowns and unknowns about CAR-T cell dysfunction. Cancers (Basel). 2022. https:\/\/doi.org\/10.3390\/cancers14041078.","journal-title":"Cancers (Basel)"},{"key":"2076_CR17","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1038\/s41571-020-00456-y","volume":"18","author":"H Shalabi","year":"2021","unstructured":"Shalabi H, et al. Beyond the storm - subacute toxicities and late effects in children receiving CAR T cells. Nat Rev Clin Oncol. 2021;18:363\u201378. https:\/\/doi.org\/10.1038\/s41571-020-00456-y.","journal-title":"Nat Rev Clin Oncol"},{"key":"2076_CR18","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1056\/NEJMoa1708566","volume":"377","author":"SJ Schuster","year":"2017","unstructured":"Schuster SJ, et al. Chimeric antigen receptor T cells in refractory B-cell lymphomas. N Engl J Med. 2017;377:2545\u201354. https:\/\/doi.org\/10.1056\/NEJMoa1708566.","journal-title":"N Engl J Med"},{"key":"2076_CR19","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","volume":"368","author":"SA Grupp","year":"2013","unstructured":"Grupp SA, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med. 2013;368:1509\u201318. https:\/\/doi.org\/10.1056\/NEJMoa1215134.","journal-title":"N Engl J Med"},{"key":"2076_CR20","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","volume":"371","author":"SL Maude","year":"2014","unstructured":"Maude SL, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014;371:1507\u201317. https:\/\/doi.org\/10.1056\/NEJMoa1407222.","journal-title":"N Engl J Med"},{"key":"2076_CR21","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1038\/s41422-022-00721-y","volume":"32","author":"Y Hu","year":"2022","unstructured":"Hu Y, et al. Genetically modified CD7-targeting allogeneic CAR-T cell therapy with enhanced efficacy for relapsed\/refractory CD7-positive hematological malignancies: a phase I clinical study. Cell Res. 2022;32:995\u20131007. https:\/\/doi.org\/10.1038\/s41422-022-00721-y.","journal-title":"Cell Res"},{"key":"2076_CR22","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abl3642","volume":"7","author":"D Vasic","year":"2022","unstructured":"Vasic D, et al. Allogeneic double-negative CAR-T cells inhibit tumor growth without off-tumor toxicities. Sci Immunol. 2022;7:eabl3642. https:\/\/doi.org\/10.1126\/sciimmunol.abl3642.","journal-title":"Sci Immunol"},{"key":"2076_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00822-w","volume":"13","author":"Y Zhang","year":"2023","unstructured":"Zhang Y, et al. Allogenic and autologous anti-CD7 CAR-T cell therapies in relapsed or refractory T-cell malignancies. Blood Cancer J. 2023;13:61. https:\/\/doi.org\/10.1038\/s41408-023-00822-w.","journal-title":"Blood Cancer J"},{"key":"2076_CR24","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00482","volume":"11","author":"M Castella","year":"2020","unstructured":"Castella M, et al. Point-of-care CAR T-cell production (ARI-0001) using a closed semi-automatic bioreactor: experience from an academic phase I clinical trial. Front Immunol. 2020;11:482. https:\/\/doi.org\/10.3389\/fimmu.2020.00482.","journal-title":"Front Immunol"},{"key":"2076_CR25","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002737","author":"JT Huckaby","year":"2021","unstructured":"Huckaby JT, et al. Bispecific binder redirected lentiviral vector enables in vivo engineering of CAR-T cells. J Immunother Cancer. 2021. https:\/\/doi.org\/10.1136\/jitc-2021-002737.","journal-title":"J Immunother Cancer"},{"key":"2076_CR26","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005189","author":"D Lock","year":"2022","unstructured":"Lock D, et al. Automated, scaled, transposon-based production of CAR T cells. J Immunother Cancer. 2022. https:\/\/doi.org\/10.1136\/jitc-2022-005189.","journal-title":"J Immunother Cancer"},{"key":"2076_CR27","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.jtha.2024.09.024","volume":"23","author":"E Friedberg","year":"2025","unstructured":"Friedberg E, et al. Disappearance of antiphospholipid antibodies after anti-CD19 chimeric antigen receptor T-cell therapy of B-cell lymphoma in a patient with systemic lupus erythematosus and antiphospholipid syndrome. J Thromb Haemost. 2025;23:262\u20136. https:\/\/doi.org\/10.1016\/j.jtha.2024.09.024.","journal-title":"J Thromb Haemost"},{"key":"2076_CR28","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2024-004727","author":"D Szabo","year":"2024","unstructured":"Szabo D, et al. Sustained drug-free remission in rheumatoid arthritis associated with diffuse large B-cell lymphoma following tandem CD20-CD19-directed non-cryopreserved CAR-T cell therapy using zamtocabtagene autoleucel. RMD Open. 2024. https:\/\/doi.org\/10.1136\/rmdopen-2024-004727.","journal-title":"RMD Open"},{"key":"2076_CR29","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1298815","volume":"14","author":"L Sheng","year":"2023","unstructured":"Sheng L, et al. Concurrent remission of lymphoma and Sj\u00f6gren\u2019s disease following anti-CD19 chimeric antigen receptor-T cell therapy for diffuse large B-cell lymphoma: a case report. Front Immunol. 2023;14:1298815. https:\/\/doi.org\/10.3389\/fimmu.2023.1298815.","journal-title":"Front Immunol"},{"key":"2076_CR30","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1038\/s41409-023-02086-1","volume":"58","author":"J Wang","year":"2023","unstructured":"Wang J, et al. CD19-targeted chimeric antigen receptor T-cell therapy in patients with concurrent B-cell Non-Hodgkin lymphoma and rheumatic autoimmune diseases: a propensity score matching study. Bone Marrow Transplant. 2023;58:1223\u20138. https:\/\/doi.org\/10.1038\/s41409-023-02086-1.","journal-title":"Bone Marrow Transplant"},{"key":"2076_CR31","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aav1648","author":"R Kansal","year":"2019","unstructured":"Kansal R, et al. Sustained B cell depletion by CD19-targeted CAR T cells is a highly effective treatment for murine lupus. Sci Transl Med. 2019. https:\/\/doi.org\/10.1126\/scitranslmed.aav1648.","journal-title":"Sci Transl Med"},{"key":"2076_CR32","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1056\/NEJMc2107725","volume":"385","author":"D Mougiakakos","year":"2021","unstructured":"Mougiakakos D, et al. CD19-Targeted CAR T Cells in Refractory Systemic Lupus Erythematosus. N Engl J Med. 2021;385:567\u20139. https:\/\/doi.org\/10.1056\/NEJMc2107725.","journal-title":"N Engl J Med"},{"key":"2076_CR33","doi-asserted-by":"publisher","first-page":"2189","DOI":"10.1097\/cm9.0000000000000983","volume":"133","author":"Y Fan","year":"2020","unstructured":"Fan Y, Hao YJ, Zhang ZL. Systemic lupus erythematosus: year in review 2019. Chin Med J (Engl). 2020;133:2189\u201396. https:\/\/doi.org\/10.1097\/cm9.0000000000000983.","journal-title":"Chin Med J (Engl)"},{"key":"2076_CR34","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/j.medcli.2020.05.009","volume":"155","author":"J Narv\u00e1ez","year":"2020","unstructured":"Narv\u00e1ez J. Systemic lupus erythematosus 2020. Med Clin (Barc). 2020;155:494\u2013501. https:\/\/doi.org\/10.1016\/j.medcli.2020.05.009.","journal-title":"Med Clin (Barc)"},{"key":"2076_CR35","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1056\/NEJMoa021933","volume":"349","author":"MR Arbuckle","year":"2003","unstructured":"Arbuckle MR, et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med. 2003;349:1526\u201333. https:\/\/doi.org\/10.1056\/NEJMoa021933.","journal-title":"N Engl J Med"},{"key":"2076_CR36","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1136\/ard-2024-226142","volume":"84","author":"C Tur","year":"2025","unstructured":"Tur C, et al. CD19-CAR T-cell therapy induces deep tissue depletion of B cells. Ann Rheum Dis. 2025;84:106\u201314. https:\/\/doi.org\/10.1136\/ard-2024-226142.","journal-title":"Ann Rheum Dis"},{"key":"2076_CR37","doi-asserted-by":"publisher","first-page":"2124","DOI":"10.1038\/s41591-022-02017-5","volume":"28","author":"A Mackensen","year":"2022","unstructured":"Mackensen A, et al. Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus. Nat Med. 2022;28:2124\u201332. https:\/\/doi.org\/10.1038\/s41591-022-02017-5.","journal-title":"Nat Med"},{"key":"2076_CR38","doi-asserted-by":"publisher","first-page":"2158","DOI":"10.1016\/s0140-6736(24)02265-7","volume":"404","author":"M Hagen","year":"2024","unstructured":"Hagen M, et al. Treatment of CNS systemic lupus erythematosus with CD19 CAR T cells. Lancet. 2024;404:2158\u201360. https:\/\/doi.org\/10.1016\/s0140-6736(24)02265-7.","journal-title":"Lancet"},{"key":"2076_CR39","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1016\/s0140-6736(24)00424-0","volume":"403","author":"T Krickau","year":"2024","unstructured":"Krickau T, et al. CAR T-cell therapy rescues adolescent with rapidly progressive lupus nephritis from haemodialysis. Lancet. 2024;403:1627\u201330. https:\/\/doi.org\/10.1016\/s0140-6736(24)00424-0.","journal-title":"Lancet"},{"key":"2076_CR40","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1056\/NEJMoa2308917","volume":"390","author":"F M\u00fcller","year":"2024","unstructured":"M\u00fcller F, et al. CD19 CAR T-cell therapy in autoimmune disease - a case series with follow-up. N Engl J Med. 2024;390:687\u2013700. https:\/\/doi.org\/10.1056\/NEJMoa2308917.","journal-title":"N Engl J Med"},{"key":"2076_CR41","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.19723\/j.issn.1671-167X.2024.06.029","volume":"56","author":"M Wang","year":"2024","unstructured":"Wang M, et al. Safe pregnancy and delivery in a female patient with systemic lupus erythematosus after discontinuation of dual-target chimeric antigen receptor T cells therapy. Beijing Da Xue Xue Bao Yi Xue Ban. 2024;56:1119\u201325. https:\/\/doi.org\/10.19723\/j.issn.1671-167X.2024.06.029.","journal-title":"Beijing Da Xue Xue Bao Yi Xue Ban"},{"key":"2076_CR42","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1136\/ard-2024-225785","volume":"83","author":"W Wang","year":"2024","unstructured":"Wang W, et al. BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial. Ann Rheum Dis. 2024;83:1304\u201314. https:\/\/doi.org\/10.1136\/ard-2024-225785.","journal-title":"Ann Rheum Dis"},{"key":"2076_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2024.103692","volume":"24","author":"X He","year":"2025","unstructured":"He X, et al. Treatment of two pediatric patients with refractory systemic lupus erythematosus using CD19-targeted CAR T-cells. Autoimmun Rev. 2025;24:103692. https:\/\/doi.org\/10.1016\/j.autrev.2024.103692.","journal-title":"Autoimmun Rev"},{"key":"2076_CR44","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1056\/NEJMc2403743","volume":"391","author":"M Li","year":"2024","unstructured":"Li M, et al. Anti-CD19 CAR T cells in refractory immune thrombocytopenia of SLE. N Engl J Med. 2024;391:376\u20138. https:\/\/doi.org\/10.1056\/NEJMc2403743.","journal-title":"N Engl J Med"},{"key":"2076_CR45","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1136\/ard-2023-223952","volume":"82","author":"C Bergmann","year":"2023","unstructured":"Bergmann C, et al. Treatment of a patient with severe systemic sclerosis (SSc) using CD19-targeted CAR T cells. Ann Rheum Dis. 2023;82:1117\u201320. https:\/\/doi.org\/10.1136\/ard-2023-223952.","journal-title":"Ann Rheum Dis"},{"key":"2076_CR46","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1136\/ard-2023-225174","volume":"83","author":"W Merkt","year":"2024","unstructured":"Merkt W, et al. Third-generation CD19.CAR-T cell-containing combination therapy in Scl70+ systemic sclerosis. Ann Rheum Dis. 2024;83:543\u20136. https:\/\/doi.org\/10.1136\/ard-2023-225174.","journal-title":"Ann Rheum Dis"},{"key":"2076_CR47","doi-asserted-by":"publisher","first-page":"4890","DOI":"10.1016\/j.cell.2024.06.027","volume":"187","author":"X Wang","year":"2024","unstructured":"Wang X, et al. Allogeneic CD19-targeted CAR-T therapy in patients with severe myositis and systemic sclerosis. Cell. 2024;187:4890\u20134904.e4899. https:\/\/doi.org\/10.1016\/j.cell.2024.06.027.","journal-title":"Cell"},{"key":"2076_CR48","doi-asserted-by":"publisher","first-page":"e83","DOI":"10.1016\/s2665-9913(24)00282-0","volume":"7","author":"J Auth","year":"2025","unstructured":"Auth J, et al. CD19-targeting CAR T-cell therapy in patients with diffuse systemic sclerosis: a case series. Lancet Rheumatol. 2025;7:e83\u201393. https:\/\/doi.org\/10.1016\/s2665-9913(24)00282-0.","journal-title":"Lancet Rheumatol"},{"key":"2076_CR49","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaf077","author":"FN Albach","year":"2025","unstructured":"Albach FN, et al. Targeting autoimmunity with CD19-CAR T cell therapy: efficacy and seroconversion in diffuse systemic sclerosis and rheumatoid arthritis. Rheumatology (Oxford). 2025. https:\/\/doi.org\/10.1093\/rheumatology\/keaf077.","journal-title":"Rheumatology (Oxford)"},{"key":"2076_CR50","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1002\/art.39501","volume":"68","author":"D Khanna","year":"2016","unstructured":"Khanna D, et al. The American College of Rheumatology provisional composite response index for clinical trials in early diffuse cutaneous systemic sclerosis. Arthritis & Rheumatology. 2016;68:299\u2013311. https:\/\/doi.org\/10.1002\/art.39501.","journal-title":"Arthritis & Rheumatology"},{"key":"2076_CR51","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1136\/annrheumdis-2020-219100","volume":"80","author":"D Khanna","year":"2021","unstructured":"Khanna D, Huang S, Lin CJF, Spino C. New composite endpoint in early diffuse cutaneous systemic sclerosis: revisiting the provisional American College of Rheumatology Composite Response Index in Systemic Sclerosis. Ann Rheum Dis. 2021;80:641\u201350. https:\/\/doi.org\/10.1136\/annrheumdis-2020-219100.","journal-title":"Ann Rheum Dis"},{"key":"2076_CR52","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1136\/annrheumdis-2016-209768","volume":"76","author":"G Valentini","year":"2017","unstructured":"Valentini G, et al. The European Scleroderma Trials and Research group (EUSTAR) task force for the development of revised activity criteria for systemic sclerosis: derivation and validation of a preliminarily revised EUSTAR activity index. Ann Rheum Dis. 2017;76:270\u20136. https:\/\/doi.org\/10.1136\/annrheumdis-2016-209768.","journal-title":"Ann Rheum Dis"},{"key":"2076_CR53","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1019972","volume":"13","author":"X Ma","year":"2022","unstructured":"Ma X, Bu BT. Anti-SRP immune-mediated necrotizing myopathy: a critical review of current concepts. Front Immunol. 2022;13:1019972. https:\/\/doi.org\/10.3389\/fimmu.2022.1019972.","journal-title":"Front Immunol"},{"key":"2076_CR54","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1051609","volume":"13","author":"C Zhen","year":"2022","unstructured":"Zhen C, et al. Efficacy and safety of rituximab treatment in patients with idiopathic inflammatory myopathies: a systematic review and meta-analysis. Front Immunol. 2022;13:1051609. https:\/\/doi.org\/10.3389\/fimmu.2022.1051609.","journal-title":"Front Immunol"},{"key":"2076_CR55","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1016\/s0140-6736(23)00023-5","volume":"401","author":"F M\u00fcller","year":"2023","unstructured":"M\u00fcller F, et al. CD19-targeted CAR T cells in refractory antisynthetase syndrome. Lancet. 2023;401:815\u20138. https:\/\/doi.org\/10.1016\/s0140-6736(23)00023-5.","journal-title":"Lancet"},{"key":"2076_CR56","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.1001\/jama.2023.8753","volume":"329","author":"AC Pecher","year":"2023","unstructured":"Pecher AC, et al. CD19-targeting CAR T cells for myositis and interstitial lung disease associated with antisynthetase syndrome. JAMA. 2023;329:2154\u201362. https:\/\/doi.org\/10.1001\/jama.2023.8753.","journal-title":"JAMA"},{"key":"2076_CR57","doi-asserted-by":"publisher","first-page":"3821","DOI":"10.1016\/j.ymthe.2024.09.009","volume":"32","author":"J Volkov","year":"2024","unstructured":"Volkov J, et al. Case study of CD19 CAR T therapy in a subject with immune-mediate necrotizing myopathy treated in the RESET-Myositis phase I\/II trial. Mol Ther. 2024;32:3821\u20138. https:\/\/doi.org\/10.1016\/j.ymthe.2024.09.009.","journal-title":"Mol Ther"},{"key":"2076_CR58","doi-asserted-by":"publisher","first-page":"e12","DOI":"10.1093\/rheumatology\/kead330","volume":"63","author":"J Taubmann","year":"2024","unstructured":"Taubmann J, et al. Rescue therapy of antisynthetase syndrome with CD19-targeted CAR-T cells after failure of several B-cell depleting antibodies. Rheumatology (Oxford). 2024;63:e12\u20134. https:\/\/doi.org\/10.1093\/rheumatology\/kead330.","journal-title":"Rheumatology (Oxford)"},{"key":"2076_CR59","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1002\/art.42933","volume":"76","author":"R Nicolai","year":"2024","unstructured":"Nicolai R, et al. Autologous CD19-targeting CAR T cells in a patient with refractory juvenile dermatomyositis. Arthritis Rheumatol. 2024;76:1560\u20135. https:\/\/doi.org\/10.1002\/art.42933.","journal-title":"Arthritis Rheumatol"},{"key":"2076_CR60","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2315990121","volume":"121","author":"C Qin","year":"2024","unstructured":"Qin C, et al. Single-cell analysis of refractory anti-SRP necrotizing myopathy treated with anti-BCMA CAR-T cell therapy. Proc Natl Acad Sci U S A. 2024;121:e2315990121. https:\/\/doi.org\/10.1073\/pnas.2315990121.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2076_CR61","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1136\/annrheumdis-2017-211400","volume":"76","author":"R Aggarwal","year":"2017","unstructured":"Aggarwal R, et al. 2016 American College of Rheumatology\/European League Against Rheumatism criteria for minimal, moderate, and major clinical response in adult dermatomyositis and polymyositis. Ann Rheum Dis. 2017;76:792\u2013801. https:\/\/doi.org\/10.1136\/annrheumdis-2017-211400.","journal-title":"Ann Rheum Dis"},{"key":"2076_CR62","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.retram.2018.03.003","volume":"66","author":"J Gauthier","year":"2018","unstructured":"Gauthier J, Turtle CJ. Insights into cytokine release syndrome and neurotoxicity after CD19-specific CAR-T cell therapy. Curr Res Transl Med. 2018;66:50\u20132. https:\/\/doi.org\/10.1016\/j.retram.2018.03.003.","journal-title":"Curr Res Transl Med"},{"key":"2076_CR63","doi-asserted-by":"publisher","DOI":"10.1007\/s00281-024-01013-w","volume":"46","author":"AD Hughes","year":"2024","unstructured":"Hughes AD, Teachey DT, Diorio C. Riding the storm: managing cytokine-related toxicities in CAR-T cell therapy. Semin Immunopathol. 2024;46:5. https:\/\/doi.org\/10.1007\/s00281-024-01013-w.","journal-title":"Semin Immunopathol"},{"key":"2076_CR64","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1056\/NEJMoa1103849","volume":"365","author":"DL Porter","year":"2011","unstructured":"Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med. 2011;365:725\u201333. https:\/\/doi.org\/10.1056\/NEJMoa1103849.","journal-title":"N Engl J Med"},{"key":"2076_CR65","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s41577-021-00547-6","volume":"22","author":"EC Morris","year":"2022","unstructured":"Morris EC, Neelapu SS, Giavridis T, Sadelain M. Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy. Nat Rev Immunol. 2022;22:85\u201396. https:\/\/doi.org\/10.1038\/s41577-021-00547-6.","journal-title":"Nat Rev Immunol"},{"key":"2076_CR66","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1016\/j.bbmt.2016.06.010","volume":"22","author":"R Abboud","year":"2016","unstructured":"Abboud R, et al. Severe cytokine-release syndrome after T cell-replete peripheral blood haploidentical donor transplantation is associated with poor survival and anti-IL-6 therapy is safe and well tolerated. Biol Blood Marrow Transplant. 2016;22:1851\u201360. https:\/\/doi.org\/10.1016\/j.bbmt.2016.06.010.","journal-title":"Biol Blood Marrow Transplant"},{"key":"2076_CR67","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/j.jaip.2021.10.037","volume":"10","author":"J Wat","year":"2022","unstructured":"Wat J, Barmettler S. Hypogammaglobulinemia after chimeric antigen receptor (CAR) T-cell therapy: characteristics, management, and future directions. J Allergy Clin Immunol Pract. 2022;10:460\u20136. https:\/\/doi.org\/10.1016\/j.jaip.2021.10.037.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2076_CR68","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1056\/NEJMoa2411507","volume":"392","author":"K Perica","year":"2025","unstructured":"Perica K, et al. CD4+ T-cell lymphoma harboring a chimeric antigen receptor integration in TP53. N Engl J Med. 2025;392:577\u201383. https:\/\/doi.org\/10.1056\/NEJMoa2411507.","journal-title":"N Engl J Med"},{"key":"2076_CR69","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1056\/NEJMoa2309728","volume":"392","author":"SJ Harrison","year":"2025","unstructured":"Harrison SJ, et al. CAR+ T-cell lymphoma after Cilta-cel therapy for relapsed or refractory myeloma. N Engl J Med. 2025;392:677\u201385. https:\/\/doi.org\/10.1056\/NEJMoa2309728.","journal-title":"N Engl J Med"},{"key":"2076_CR70","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2020.100757","volume":"46","author":"C Poh","year":"2021","unstructured":"Poh C, Keegan T, Rosenberg AS. Second primary malignancies in multiple myeloma: a review. Blood Rev. 2021;46:100757. https:\/\/doi.org\/10.1016\/j.blre.2020.100757.","journal-title":"Blood Rev"},{"key":"2076_CR71","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1056\/NEJMp2400209","volume":"390","author":"N Verdun","year":"2024","unstructured":"Verdun N, Marks P. Secondary cancers after chimeric antigen receptor T-cell therapy. N Engl J Med. 2024;390:584\u20136. https:\/\/doi.org\/10.1056\/NEJMp2400209.","journal-title":"N Engl J Med"},{"key":"2076_CR72","doi-asserted-by":"publisher","first-page":"e424","DOI":"10.1016\/s2665-9913(25)00091-8","volume":"7","author":"M Hagen","year":"2025","unstructured":"Hagen M, et al. Local immune effector cell-associated toxicity syndrome in CAR T-cell treated patients with autoimmune disease: an observational study. Lancet Rheumatol. 2025;7:e424\u201333. https:\/\/doi.org\/10.1016\/s2665-9913(25)00091-8.","journal-title":"Lancet Rheumatol"},{"key":"2076_CR73","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.ard.2025.05.096","volume":"84","author":"C Wu","year":"2025","unstructured":"Wu C, et al. OP0074 Preliminary results of CD19\/BCMA dual-targeting FasTCAR-T Cells GC012F (AZD0120) in patients with refractory systemic lupus erythematosus-an open-label, single-arm study. Ann Rheum Dis. 2025;84:65. https:\/\/doi.org\/10.1016\/j.ard.2025.05.096.","journal-title":"Ann Rheum Dis"},{"key":"2076_CR74","doi-asserted-by":"publisher","first-page":"5579","DOI":"10.1182\/bloodadvances.2023010302","volume":"7","author":"M Scordo","year":"2023","unstructured":"Scordo M, et al. Identifying an optimal fludarabine exposure for improved outcomes after axi-cel therapy for aggressive B-cell non-Hodgkin lymphoma. Blood Adv. 2023;7:5579\u201385. https:\/\/doi.org\/10.1182\/bloodadvances.2023010302.","journal-title":"Blood Adv"},{"key":"2076_CR75","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2025015928","author":"JC Panetta","year":"2025","unstructured":"Panetta JC, Talleur AC, Naik S, Gottschalk S, Leggas M. Age-adjusted dosing of fludarabine for lymphodepletion in CAR T-cell therapy: a clinical trial simulation study. Blood Adv. 2025. https:\/\/doi.org\/10.1182\/bloodadvances.2025015928.","journal-title":"Blood Adv"},{"key":"2076_CR76","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1016\/j.ard.2025.05.457","volume":"84","author":"J Goulding","year":"2025","unstructured":"Goulding J, et al. POS0060 Next-generation off-the-shelf CAR T cells: a novel platform to enable comprehensive elimination of aberrant effector cells for the treatment of autoimmune diseases in the absence of conditioning chemotherapy. Ann Rheum Dis. 2025;84:368. https:\/\/doi.org\/10.1016\/j.ard.2025.05.457.","journal-title":"Ann Rheum Dis"},{"key":"2076_CR77","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.ard.2025.05.318","volume":"84","author":"T Mozaffar","year":"2025","unstructured":"Mozaffar T, et al. OP0316 Reset-myositistm: clinical trial evaluating rese-cel (resecabtagene autoleucel), a fully human, autologous 4-1BB ANTI-CD19 CAR T cell therapy in idiopathic inflammatory myopathies. Ann Rheum Dis. 2025;84:254\u20135. https:\/\/doi.org\/10.1016\/j.ard.2025.05.318.","journal-title":"Ann Rheum Dis"},{"key":"2076_CR78","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.ard.2025.05.214","volume":"84","author":"S Sheikh","year":"2025","unstructured":"Sheikh S, et al. OP0202 Reset-sle: clinical trial evaluating rese-cel (resecabtagene autoleucel), a fully human, autologous 4-1BB ANTI-CD19 CAR T cell therapy in non-renal sle and lupus nephritis. Ann Rheum Dis. 2025;84:168. https:\/\/doi.org\/10.1016\/j.ard.2025.05.214.","journal-title":"Ann Rheum Dis"},{"key":"2076_CR79","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.ard.2025.05.340","volume":"84","author":"D Khanna","year":"2025","unstructured":"Khanna D, et al. OP0338 Reset- SScTM: clinical trial evaluating rese-cel (resecabtagene autoleucel), a fully human, autologous 4-1BB ANTI-CD19 CAR T cell therapy in systemic sclerosis. Ann Rheum Dis. 2025;84:275\u20136. https:\/\/doi.org\/10.1016\/j.ard.2025.05.340.","journal-title":"Ann Rheum Dis"},{"key":"2076_CR80","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.ard.2025.05.339","volume":"84","author":"C Bergmann","year":"2025","unstructured":"Bergmann C, et al. OP0337 Trajectories of the eustar AI, ACR criss and revised criss upon CD19. CART treatment in patients with diffuse cutaneous systemic sclerosis. Ann Rheum Dis. 2025;84:274\u20135. https:\/\/doi.org\/10.1016\/j.ard.2025.05.339.","journal-title":"Ann Rheum Dis"},{"key":"2076_CR81","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1016\/j.ard.2025.05.863","volume":"84","author":"M Doglio","year":"2025","unstructured":"Doglio M, et al. POS0481 \u201cReal World\u201d incidence and characteristics of immune effector cell\u2013associated hemophagocytic lymphohisticytosis: a GoCart coalition study on behalf of the European Bone Marrow TraNsplantation (EBMT) Autoimmune Disease Working Party (ADWP), Cellular Therapy Working Party (CTIWP) and transplant Complication Working Party(TCWP). Ann Rheum Dis. 2025;84:702. https:\/\/doi.org\/10.1016\/j.ard.2025.05.863.","journal-title":"Ann Rheum Dis"},{"key":"2076_CR82","doi-asserted-by":"publisher","first-page":"E374","DOI":"10.1002\/ajh.26668","volume":"97","author":"S Priyadarshini","year":"2022","unstructured":"Priyadarshini S, et al. Hemophagocytic lymphohistiocytosis secondary to CAR-T cells: update from the FDA and Vizient databases. Am J Hematol. 2022;97:E374\u20136. https:\/\/doi.org\/10.1002\/ajh.26668.","journal-title":"Am J Hematol"},{"key":"2076_CR83","doi-asserted-by":"publisher","first-page":"438.e431","DOI":"10.1016\/j.jtct.2023.03.006","volume":"29","author":"MR Hines","year":"2023","unstructured":"Hines MR, et al. Immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome. Transplant Cell Ther. 2023;29:438.e431\u2013438.e416. https:\/\/doi.org\/10.1016\/j.jtct.2023.03.006.","journal-title":"Transplant Cell Ther"},{"key":"2076_CR84","doi-asserted-by":"publisher","unstructured":"Huihua Ding, e. a. Abstract supplement ACR convergence 2025. Arthritis & Rheumatology 2025;77. https:\/\/doi.org\/10.1002\/art.43421","DOI":"10.1002\/art.43421"},{"key":"2076_CR85","doi-asserted-by":"publisher","unstructured":"Brian Kim, e. a. Abstract supplement ACR convergence 2025. Arthritis & Rheumatology 2025;77. https:\/\/doi.org\/10.1002\/art.43421","DOI":"10.1002\/art.43421"},{"key":"2076_CR86","doi-asserted-by":"publisher","unstructured":"Merle Freitag, e. a. Abstract supplement ACR convergence 2025. Arthritis & Rheumatology 2025;77. https:\/\/doi.org\/10.1002\/art.43421","DOI":"10.1002\/art.43421"},{"key":"2076_CR87","doi-asserted-by":"publisher","unstructured":"Ehsan Dehdashtian, e. a. Abstract supplement ACR convergence 2025. Arthritis & Rheumatology 2025;77. https:\/\/doi.org\/10.1002\/art.43421","DOI":"10.1002\/art.43421"},{"key":"2076_CR88","doi-asserted-by":"publisher","unstructured":"Asrith Reddy Gandu, e. a. Abstract supplement ACR convergence 2025. Arthritis & Rheumatology 2025;77. https:\/\/doi.org\/10.1002\/art.43421","DOI":"10.1002\/art.43421"},{"key":"2076_CR89","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1038\/nrrheum.2014.33","volume":"10","author":"FB Vincent","year":"2014","unstructured":"Vincent FB, Morand EF, Schneider P, Mackay F. The BAFF\/APRIL system in SLE pathogenesis. Nat Rev Rheumatol. 2014;10:365\u201373. https:\/\/doi.org\/10.1038\/nrrheum.2014.33.","journal-title":"Nat Rev Rheumatol"},{"key":"2076_CR90","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.semarthrit.2015.08.001","volume":"45","author":"BK Han","year":"2016","unstructured":"Han BK, Olsen NJ, Bottaro A. The CD27-CD70 pathway and pathogenesis of autoimmune disease. Semin Arthritis Rheum. 2016;45:496\u2013501. https:\/\/doi.org\/10.1016\/j.semarthrit.2015.08.001.","journal-title":"Semin Arthritis Rheum"},{"key":"2076_CR91","unstructured":"A Phase 1 Study Evaluating the Safety and Preliminary Efficacy of ALLO-329, a Dual Anti-CD19\/Anti-CD70 Allogeneic CAR T Cell Product in Autoimmune Disease(2025\/07\/25).https:\/\/clinicaltrials.gov\/study\/NCT07085104."},{"key":"2076_CR92","unstructured":"Study of Ultra-Fast Autologous BCMA\/CD70-Targeted Chimeric Antigen Receptor T (CAR- T) Therapy for Refractory Systemic Lupus Erythematosus(2026\/01\/05).https:\/\/clinicaltrials.gov\/study\/NCT07318259."},{"key":"2076_CR93","unstructured":"A Clinical Study of the Safety and Efficacy of Universal Anti-CD70 CAR-T (CHT101) for the Treatment of Relapsed and Refractory Systemic Lupus Erythematosus(2025\/10\/03).https:\/\/clinicaltrials.gov\/study\/NCT06946485."},{"key":"2076_CR94","unstructured":"Study of BCMA\/CD70 Targeted Chimeric Antigen Receptor T (CAR- T) Therapy for Refractory Childhood-oneset Systemic Lupus Erythematosus(2025\/04\/25). https:\/\/clinicaltrials.gov\/study\/NCT06934447."},{"key":"2076_CR95","unstructured":"A Phase I Study of BAFF CAR-T Cells (LMY-920) for Treatment of Systemic Lupus Erythematosus(2025\/06\/03). https:\/\/clinicaltrials.gov\/study\/NCT06340750."},{"key":"2076_CR96","doi-asserted-by":"publisher","first-page":"12450","DOI":"10.1021\/jacs.7b03208","volume":"139","author":"W Peng","year":"2017","unstructured":"Peng W, Paulson JC. Ligands on a natural N-Glycan scaffold efficiently deliver toxins to B-Lymphoma cells. J Am Chem Soc. 2017;139:12450\u20138. https:\/\/doi.org\/10.1021\/jacs.7b03208.","journal-title":"J Am Chem Soc"},{"key":"2076_CR97","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/s11523-020-00729-7","volume":"15","author":"S Ding","year":"2020","unstructured":"Ding S, et al. Targeting CD79b for chimeric antigen receptor T-cell therapy of B-cell lymphomas. Target Oncol. 2020;15:365\u201375. https:\/\/doi.org\/10.1007\/s11523-020-00729-7.","journal-title":"Target Oncol"},{"key":"2076_CR98","doi-asserted-by":"publisher","first-page":"3083","DOI":"10.1182\/blood-2016-05-715094","volume":"128","author":"ZY Xu-Monette","year":"2016","unstructured":"Xu-Monette ZY, et al. Assessment of CD37 B-cell antigen and cell of origin significantly improves risk prediction in diffuse large B-cell lymphoma. Blood. 2016;128:3083\u2013100. https:\/\/doi.org\/10.1182\/blood-2016-05-715094.","journal-title":"Blood"},{"key":"2076_CR99","unstructured":"Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of Moderate to Severe Active SLE Clinical Research(2025\/04\/04). https:\/\/clinicaltrials.gov\/study\/NCT06711146."},{"key":"2076_CR100","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1056\/NEJMoa2408771","volume":"392","author":"J Svoboda","year":"2025","unstructured":"Svoboda J, et al. Enhanced CAR T-cell therapy for lymphoma after previous failure. N Engl J Med. 2025;392:1824\u201335. https:\/\/doi.org\/10.1056\/NEJMoa2408771.","journal-title":"N Engl J Med"},{"key":"2076_CR101","unstructured":"A Phase lb Open-Label Study Evaluating the Safety and Efficacy of the Combination of CLBR00l, an Engineered Autologous T Cell Product, and SWI019, a CD19-directed Antibody-based Biologic With or Without Lymphodepletion in Subjects With Autoimmune Disorders Including Systemic Lupus Erythematosus, Systemic Sclerosis, or Idiopathic Inflammatory Myositis(2025\/04\/06). https:\/\/clinicaltrials.gov\/study\/NCT06913608."}],"container-title":["Clinical and Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10238-026-02076-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-026-02076-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-026-02076-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T17:02:47Z","timestamp":1773248567000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10238-026-02076-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,7]]},"references-count":101,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2076"],"URL":"https:\/\/doi.org\/10.1007\/s10238-026-02076-9","relation":{},"ISSN":["1591-9528"],"issn-type":[{"value":"1591-9528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,7]]},"assertion":[{"value":"6 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study strictly adhered to the Declaration of Helsinki principles for medical research involving human subjects.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors declare no competing interests relevant to this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"177"}}